The ASCP Annual Meeting is the premiere meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information.
See HealthCore’s latest research in psychopharmacology. Registration is required to view presentations. For more information, go to https://ascpp.org/ascp-meetings/ascp-annual-meeting/.
Th-23 | Decisions to Continue, Switch, or Discontinue Antidepressants Among Patients with Major Depressive Disorder: Outcomes from a Real-World, Evidence-Based Survey with a Focus on Sexual Dysfunction
Stephenson JJ1, Touya M2, Lawrence DF3, Chrones L3, Teng CC1, Clayton AH4
1HealthCore, Inc., Wilmington, DE, 2Lundbeck LLC, Deerfield, IL, 3Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA, 4University of Virginia, Charlottesville, VA
*HealthCore authors are indicated in bold.